

1-31-05

1632
\$1.82

Express Mail No.: EV 452 774 245 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Chen et al.	Confirmation No.:	7224
Serial No.:	09/735,296	Art Unit:	1632
Filed:	January 14, 2000	Examiner:	Li, Qian Janice
For:	COMBINATION THERAPY OF CANCER BY THE ACTIVATION OF CO- STIMULATORY MOLECULES EXPRESSED BY IMMUNE CELLS AND CYTOKINES	Attorney Docket No:	6923-084

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97 & §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to the references **C04-C06** listed on the attached revised PTO-1449 Form. Copies of references **C04-C06** are enclosed.

Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application. Applicants submit herewith a "revised form PTO 1449" entitled "List of References Cited" instead of an "Information Disclosure Citation in an Application".

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c)(2), since this Information Disclosure Statement is being filed before the mailing date of any of a final action under § 1.113, a notice of allowance under

§ 1.311, or an action that otherwise closes prosecution in the application, the fee required to be filed with the accompanying Information Disclosure Statement has been estimated to be \$180.00.

However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.

Date: January 27, 2005

Respectfully submitted,

Laura A. Coruzzi

Laura A. Coruzzi

30,742

(Reg. No.)

JONES DAY


222 East 41st Street

New York, New York 10017

(212) 326-3939

Enclosures

By: *Jennifer J. Chiodo*
Reg No. 46,617



Express Mail No.: EV 452 774 245 US

Sheet 1 of 1

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

6923-084-999

APPLICATION NO

09/735,296

APPLICANT

Chen et al.

FILING DATE

January 14, 2000

GROUP

1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01						
	A02						
	A03						
	A04						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01							
	B02							
	B03							
	B04							
	B05							

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C04	Kim et al., 2000, Gene therapy for established murine collagen-induced arthritis by local and systemic adenovirus-mediated delivery of interleukin-4. Arthritis Res. 2:293-302.
	C05	Etgen et al., 1999, In vivo adenoviral delivery of recombinant human protein kinase C- ζ stimulates glucose transport activity in rat skeletal muscle. J. Biol. Chem. 274:22139-22142.
	C06	Cheuk et al., 2004, Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Therapy 11:215-226.
	C07	
	C08	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.